Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 5/20 | 1.00 |
| ▸ | FAAH | O00519 | 2/20 | 0.84 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.84 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.56 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.55 |
| ▸ | ADH1B | P00325 | 1/20 | 0.55 |
| ▸ | ADH1C | P00326 | 1/20 | 0.55 |
| ▸ | ADH1A | P07327 | 1/20 | 0.55 |
| ▸ | ADH4 | P08319 | 1/20 | 0.55 |
| ▸ | ADH7 | P40394 | 1/20 | 0.55 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.53 |
| ▸ | THRB | P10828 | 1/20 | 0.50 |
| ▸ | EP300 | Q09472 | 1/20 | 0.46 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Nonanal SCHEMBL1697203 | 1.00 | TSHR (1.00) | TSHRFAAHTRPV1ALDH1A1EPHX1 | |
| SCHEMBL154928 | 1.00 | TSHR (1.00) | TSHRFAAHTRPV1ALDH1A1EPHX1 | |
| Undecanal SCHEMBL1871746 | 1.00 | TSHR (1.00) | TSHRFAAHTRPV1ALDH1A1EPHX1 | |
| SCHEMBL3118926 | 1.00 | TSHR (1.00) | TSHRFAAHTRPV1ALDH1A1EPHX1 | |
| SCHEMBL3190497 | 1.00 | TSHR (1.00) | TSHRFAAHTRPV1ALDH1A1EPHX1 | |
| Decanal SCHEMBL10857921 | 1.00 | TSHR (1.00) | TSHRFAAHTRPV1ALDH1A1EPHX1 | |
| SCHEMBL371480 | 1.00 | TSHR (1.00) | TSHRFAAHTRPV1ALDH1A1EPHX1 | |
| SCHEMBL1696133 | 1.00 | TSHR (1.00) | TSHRFAAHTRPV1ALDH1A1EPHX1 | |
| Tetradecanal SCHEMBL10857929 | 1.00 | TSHR (1.00) | TSHRFAAHTRPV1ALDH1A1EPHX1 | |
| SCHEMBL15136035 | 1.00 | TSHR (1.00) | TSHRFAAHTRPV1ALDH1A1EPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 194 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4608553-A1 | HETEROGENEOUS CATALYSTS | DOW GLOBAL TECHNOLOGIES LLC (US) | 2025-09-03 | — | — | EP | disclosed |
| EP-4448171-B1 | TRANSITION METAL COMPLEX HYDROFORMYLATION CATALYST PRECUROR COMPOSITIONS COMPRISING SUCH COMPOUNDS, AND HYDROFORMYLATION PROCESSES | DOW TECHNOLOGY INVESTMENTS LLC (US) | 2025-08-20 | — | — | EP | disclosed |
| EP-4448170-B1 | COMPOUNDS, TRANSITION METAL COMPLEX HYDROFORMYLATION CATALYST PRECUROR COMPOSITIONS COMPRISING SUCH COMPOUNDS, AND HYDROFORMYLATION PROCESSES | DOW TECHNOLOGY INVESTMENTS LLC (US) | 2025-08-20 | — | — | EP | disclosed |
| US-12350254-B2 | Tumescent infiltration drug delivery of cannabinoids | HK TUMESCENT PHARMA (US) | 2025-07-08 | — | — | US | disclosed |
| CN-120152789-A | Heterogeneous catalyst | 陶氏环球技术有限责任公司 | 2025-06-13 | — | — | CN | disclosed |
| CN-120092010-A | Polycyclic poly (ADP-ribose) polymerase selective inhibitors | 轩竹生物科技股份有限公司 | 2025-06-03 | — | — | CN | disclosed |
| US-12303591-B2 | Tumescent infiltration drug delivery of high subcutaneous drug concentrations with prolonged local and systemic effects and minimal local or systemic toxicity | HK TUMESCENT PHARMA (US) | 2025-05-20 | — | — | US | disclosed |
| CN-119306732-B | Bioactive substance conjugate, preparation method and application thereof | 四川科伦博泰生物医药股份有限公司 | 2025-04-25 | — | — | CN | disclosed |
| US-20250127893-A1 | EGFR TARGETED THERAPY | KERSTEN CHRISTIAN (NO) | 2025-04-24 | — | — | US | disclosed |
| US-20250128245-A1 | COMPOUNDS, TRANSITION METAL COMPLEX HYDROFORMYLATION CATALYST PRECUROR COMPOSITIONS COMPRISING SUCH COMPOUNDS, AND HYDROFORMYLATION PROCESSES | DOW TECHNOLOGY INVESTMENTS LLC (US) | 2025-04-24 | — | — | US | disclosed |
| CN-1032243-C | Reactivation of hydroformylation catalysts | UNION CARBIDE CHEM PLASTIC (US) | 1996-07-10 | — | — | CN | disclosed |
| CN-1087619-A | The separation method of catalyst-aldehde product | UNION CARBIDE CHEM PLASTIC (US) | 1994-06-08 | — | — | CN | disclosed |
| CN-1087620-A | The separation method of catalyst-aldehde product | UNION CARBIDE CHEM PLASTIC (US) | 1994-06-08 | — | — | CN | disclosed |
| CN-1024186-C | Process for the separation of catalyst aldehyde product | UNION CARBIDE CORP (US) | 1994-04-13 | — | — | CN | disclosed |
| CN-1066009-A | The reactivation of carbonylation reaction catalyst | UNION CARBIDE CHEM PLASTIC (US) | 1992-11-11 | — | — | CN | disclosed |
| CN-1046731-A | Process for the separation of catalyst aldehyde product | UNION CARBIDE CORP (US) | 1990-11-07 | — | — | CN | disclosed |
| EP-0111241-B1 | RUBBERY POLYCARBONATES | GENERAL ELECTRIC COMPANY (US) | 1989-11-08 | — | — | EP | disclosed |
| US-4535191-A | TO MAKE NONEL POLYCARBONATES | GENERAL ELECTRIC COMPANY (US) | 1985-08-13 | — | — | US | disclosed |
| EP-0111241-A2 | Rubbery polycarbonates | GENERAL ELECTRIC COMPANY (US) | 1984-06-20 | — | — | EP | disclosed |
| US-4446285-A | FROM 1,1-ALKYLIDENEDIPHENOL | GENERAL ELECTRIC COMPANY (US) | 1984-05-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250128245-A1 | COMPOUNDS, TRANSITION METAL COMPLEX HYDROFORMYLATION CATALYST PRECUROR COMPOSITIONS COMPRISING SUCH COMPOUNDS, AND HYDROFORMYLATION PROCESSES | C1R, M6PR, FOLR1 | TSHR 359/4885FAAH 4591/4885TRPV1 2174/4885 |
| US-12350254-B2 | Tumescent infiltration drug delivery of cannabinoids | CNR1, CNR2, OPRM1 | TSHR 364/4885FAAH 4/4885TRPV1 17/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.